Press Release [EN]

VLP Therapeutics Appoints Jacob Licht as Chief Operating Officer

2017.07.21|

Gaithersburg, Md. — July 21, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer. Mr. Licht comes to VLP Therapeutics with nearly 20 years of business development and strategy experience

VLP Therapeutics Announces Convertible Note Investment from TomyK Ltd. for Accelerating Cancer Vaccine Development

2017.05.09|

Gaithersburg, Md. — May 9, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it completed a convertible note financing with an angel investor Dr. Tomy Kamada, through his investment firm TomyK Ltd., that supports technology startups which

VLP Therapeutics Receives Notice of Allowance of Key U.S. composition of matter Patent for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP

2017.04.19|

Patent covers a composition of matter for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP and method of use for cancer therapy Gaithersburg, Md. — April 19, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it successfully received a

VLP Therapeutics Appoints Danai Brooks, Managing Partner of Glen Echo Capital, to Advisory Board

2017.03.01|

Gaithersburg, Md. — February 27, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that Danai Brooks, Managing Partner of Glen Echo Capital, has agreed to join VLP’s Advisory Board.  Mr. Brooks is an experienced biotechnology executive, having led

VLP Therapeutics Receives Grant from Global Health Innovative Technology (GHIT) Fund to Develop New Vaccine for Dengue Fever

2016.10.05|

Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology Fund (“the GHIT Fund”) for early-stage research to develop new vaccines for dengue fever using virus-like particles that would target all four strains of the

VLP Therapeutics Wins $2.4M U.S. Army Medical Research Grant

2016.07.14|

Gaithersburg, Md.-- (PR NEWS WIRE) — July 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that it won a $2.4 million Peer Reviewed Medical Research Program Technology/Therapeutic

VLP Therapeutics Appoints Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center as Scientific Advisor

2016.03.15|

Gaithersburg, Md.— March 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary i-α VLP vaccine technology, today announced that Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center, has

VLP Therapeutics Wins Maryland Industrial Partnerships Grant Award

2016.02.27|

Gaithersburg, Md.-- (PR NEWS WIRE) — February 27, 2016 -- VLP Therapeutics LLC (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next-generation antibody agents based upon a novel and proprietary i-α VLP vaccine technology, today announced that it received a Maryland Industrial Partnership (MIPS) grant award

VLP Therapeutics Announces Issuance of U.S. Composition of Matter Patent for i-α Virus Like Particle Platform Technology – Intellectual Property Estate Strengthens Malaria, Dengue and Zika Virus Disease Program –

2016.02.08|

Gaithersburg, Md.—February 8, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle Composition. The patent protects key composition of matter of VLP’s proprietary i-α virus like particles platform technology, and the pharmaceutical composition and vaccine for use

VLP Therapeutics to Present at 2015 Dasan Conference

2015.12.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, was invited to speak at the 2015 Dasan Conference in Busan, Korea on Wednesday, December 2, 2015, at 3:00 p.m. Local Time. The event, which is hosted by the Korean Federation of Science and Technology Societies (KOFST) is titled “the Development of Novel Technology for the Preparedness of Emerging and Unknown Infectious Diseases”and take place at Saintmare, Busan, Korea.